Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors

Abstract Advances in cancer immunology have increased the use of immune checkpoint inhibitors in clinical practice, however not all patients respond, and treatment can have severe side-effects. Blood-based immunological biomarkers are an attractive method for predicting which patients will respond t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sarah J. Dart, Alistair M. Cook, Michael J. Millward, Alison M. McDonnell, Wee L. Chin, Muhammad U. Hakeem, Tarek M. Meniawy, Samantha E. Bowyer
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9d283bf0f1db4f83be33e5ef052e4ddd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9d283bf0f1db4f83be33e5ef052e4ddd
record_format	dspace
spelling	oai:doaj.org-article:9d283bf0f1db4f83be33e5ef052e4ddd2021-12-02T18:46:57ZChanges in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors10.1038/s41598-021-93479-z2045-2322https://doaj.org/article/9d283bf0f1db4f83be33e5ef052e4ddd2021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93479-zhttps://doaj.org/toc/2045-2322Abstract Advances in cancer immunology have increased the use of immune checkpoint inhibitors in clinical practice, however not all patients respond, and treatment can have severe side-effects. Blood-based immunological biomarkers are an attractive method for predicting which patients will respond to therapy, however, reliable biomarkers for immune checkpoint blockade are lacking. This study aimed to identify patients before or early in treatment who would best respond to PD-1 inhibitors. We hypothesised that higher baseline PD-L1 and/or PD-1 on peripheral blood T cells could predict radiological response to PD-1 inhibitors. This pilot prospective cohort study assessed 26 patients with melanoma or non-small cell lung cancer, treated with pembrolizumab, nivolumab, or nivolumab/ipilimumab combined. Response was assessed by RECIST 1.1. Peripheral blood lymphocytes collected at baseline, after one cycle, 10 weeks and at discontinuation of therapy were analysed by flow cytometry. Patients with a higher proportion of PD-L1+ T cells at baseline had improved objective response to PD-1 inhibitor therapy, and patients with a lower proportion of regulatory T cells at baseline experienced more immune-related adverse events. These findings may prove useful to assist in clinical decision making. Further studies with larger cohorts are required to validate these findings.Sarah J. DartAlistair M. CookMichael J. MillwardAlison M. McDonnellWee L. ChinMuhammad U. HakeemTarek M. MeniawySamantha E. BowyerNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Sarah J. Dart Alistair M. Cook Michael J. Millward Alison M. McDonnell Wee L. Chin Muhammad U. Hakeem Tarek M. Meniawy Samantha E. Bowyer Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
description	Abstract Advances in cancer immunology have increased the use of immune checkpoint inhibitors in clinical practice, however not all patients respond, and treatment can have severe side-effects. Blood-based immunological biomarkers are an attractive method for predicting which patients will respond to therapy, however, reliable biomarkers for immune checkpoint blockade are lacking. This study aimed to identify patients before or early in treatment who would best respond to PD-1 inhibitors. We hypothesised that higher baseline PD-L1 and/or PD-1 on peripheral blood T cells could predict radiological response to PD-1 inhibitors. This pilot prospective cohort study assessed 26 patients with melanoma or non-small cell lung cancer, treated with pembrolizumab, nivolumab, or nivolumab/ipilimumab combined. Response was assessed by RECIST 1.1. Peripheral blood lymphocytes collected at baseline, after one cycle, 10 weeks and at discontinuation of therapy were analysed by flow cytometry. Patients with a higher proportion of PD-L1+ T cells at baseline had improved objective response to PD-1 inhibitor therapy, and patients with a lower proportion of regulatory T cells at baseline experienced more immune-related adverse events. These findings may prove useful to assist in clinical decision making. Further studies with larger cohorts are required to validate these findings.
format	article
author	Sarah J. Dart Alistair M. Cook Michael J. Millward Alison M. McDonnell Wee L. Chin Muhammad U. Hakeem Tarek M. Meniawy Samantha E. Bowyer
author_facet	Sarah J. Dart Alistair M. Cook Michael J. Millward Alison M. McDonnell Wee L. Chin Muhammad U. Hakeem Tarek M. Meniawy Samantha E. Bowyer
author_sort	Sarah J. Dart
title	Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
title_short	Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
title_full	Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
title_fullStr	Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
title_full_unstemmed	Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors
title_sort	changes in expression of pd-l1 on peripheral t cells in patients with melanoma and lung cancer treated with pd-1 inhibitors
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/9d283bf0f1db4f83be33e5ef052e4ddd
work_keys_str_mv	AT sarahjdart changesinexpressionofpdl1onperipheraltcellsinpatientswithmelanomaandlungcancertreatedwithpd1inhibitors AT alistairmcook changesinexpressionofpdl1onperipheraltcellsinpatientswithmelanomaandlungcancertreatedwithpd1inhibitors AT michaeljmillward changesinexpressionofpdl1onperipheraltcellsinpatientswithmelanomaandlungcancertreatedwithpd1inhibitors AT alisonmmcdonnell changesinexpressionofpdl1onperipheraltcellsinpatientswithmelanomaandlungcancertreatedwithpd1inhibitors AT weelchin changesinexpressionofpdl1onperipheraltcellsinpatientswithmelanomaandlungcancertreatedwithpd1inhibitors AT muhammaduhakeem changesinexpressionofpdl1onperipheraltcellsinpatientswithmelanomaandlungcancertreatedwithpd1inhibitors AT tarekmmeniawy changesinexpressionofpdl1onperipheraltcellsinpatientswithmelanomaandlungcancertreatedwithpd1inhibitors AT samanthaebowyer changesinexpressionofpdl1onperipheraltcellsinpatientswithmelanomaandlungcancertreatedwithpd1inhibitors
_version_	1718377695485624320

Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors

Ejemplares similares